Dr. Costales on Study of Adjuvant Therapy in Uterine Leiomyosarcoma

Video

In Partnership With:

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

This study aimed to characterize the efficacy of adjuvant therapy versus observation in women with early-stage uterine confine leiomyosarcoma following complete resection. This is a rare tumor type, Costales says, so they used the National Cancer Database to gather 1000 patients for evaluation.

Investigators were able to evaluate patients from 3 tumor types—leiomyosarcoma, epithelioid leiomyosarcoma, and myxoid leiomyosarcoma. Patients were then stratified based on adjuvant therapy such as chemotherapy, radiation, chemoradiation, or observation. Statistical software provided by the National Cancer Database was then utilized to analyze particular factors associated with trends of either adjuvant treatment or observation, explains Costales.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD